Out-Licensing of Internally Discovered Compounds and External Development and Commercialization Partnerships
First written in FY2018-Q3. 4 of 9 entries say "Advanced", first in FY2019-Q2. Latest entry: FY2022.
Ono Pharmaceutical moved to the "Worse" side of this theme in 2022.
The whole theme swung hardest in 2022: 1 of 12 companies on the "Worse" side.
0 other companies' latest entry also says "Softened".
- FY2022SoftenedAnnual report
「For the BTK inhibitor ONO-4059, the company out-licensed it to US-based Gilead in 2014. In addition to the rights to develop and commercialize it in the oncology field, which had already been returned, the corresponding rights outside the oncology field were returned during the fiscal year.」
For ONO-4059, the rights outside the oncology field were also returned in addition to the oncology rights already returned, further narrowing the scope of rights out-licensed to the external partner. - FY2022-Q3SoftenedAnnual report
「* Regarding ONO-4059, the company out-licensed it to US-based Gilead in 2014, but the rights outside the oncology field within Gilead's territory were also returned. The rights in the oncology field had already been returned.」
In addition to the oncology rights that had already been returned, the rights outside the oncology field were also returned for ONO-4059, further narrowing the scope of rights out-licensed to the external partner. - FY2021-Q3SoftenedAnnual report
「* Regarding ONO-4059, the company out-licensed it to US-based Gilead in 2014, but the rights in the oncology field within Gilead's territory were returned. Gilead continues to hold the rights outside the oncology field.」
For ONO-4059, the rights in the oncology field within Gilead's territory were returned, narrowing the scope of out-licensing and external development. - FY2021-Q3AdvancedAnnual report
「The company | Roche | Switzerland | Technology related to anti-PD-L1 antibodies | Upfront payment | Royalties | From 2020.11 until the expiration year of the applicable patents」
The company entered into a license agreement with Roche in November 2020 concerning patents related to anti-PD-L1 antibodies, giving concrete form to the out-licensing arrangement under which it receives upfront and royalty payments. The upfront payment is recorded as other income. - FY2020-Q2AdvancedAnnual report
「In July this year, Bayer, Bristol Myers Squibb and the company entered into a 3-party development collaboration agreement to evaluate combination therapy with Bayer's multikinase inhibitor Stivarga (regorafenib) and Bristol Myers Squibb / Ono Pharmaceutical's anti-PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in patients with metastatic colorectal cancer and the highest frequency of microsatellite-stable status among metastatic colorectal cancer patients.」
Bayer, Bristol Myers Squibb and the company entered into a 3-party development collaboration agreement to evaluate combination therapy with regorafenib and Opdivo, expanding development cooperation with external companies. - FY2019-Q3AdvancedAnnual report
「ONO-4059 / tirabrutinib | New active ingredient | B-cell lymphoma / Bruton's tyrosine kinase (BTK) inhibition | Tablets | II | Europe | In-house (out-licensed to Gilead Sciences)」
The development pipeline lists the out-licensing of the internally discovered ONO-4059 (tirabrutinib) to Gilead Sciences, giving concrete form to external development and commercialization cooperation. - FY2019-Q2AdvancedAnnual report
「The company | Regeneron / Sanofi | United States / France | Technology related to anti-PD-1 antibodies | Upfront payment | Royalties | From 2018.8 until the expiration year of the applicable patents」
The company entered into an agreement with Regeneron and Sanofi in August 2018 to out-license technology related to anti-PD-1 antibodies, adding an external development and commercialization partnership involving upfront and royalty payments. - FY2018RestatedAnnual report
「In December last year, we entered into a license agreement with Bristol Myers Squibb to develop and commercialize ONO-4578, a selective antagonist of the EP4 receptor, one of the prostaglandin E2 receptors, for the entire world excluding Japan, South Korea, Taiwan, China and the ASEAN countries.」
The annual report reconfirmed the policy of out-licensing the internally discovered compound ONO-4578 to an external partner for joint development and commercialization. - FY2018-Q3First statedAnnual report
「The company | Bristol Myers Squibb | United States | Agreement for the development and sale of ONO-4578 and a PGE2 receptor antagonist | Upfront payment | Royalties | From 2017.12 until all payments have been completed」
For the first time, the company disclosed that it entered into an out-licensing agreement with Bristol Myers Squibb in December 2017 for the development and sale of its internally developed compound ONO-4578 and a PGE2 receptor antagonist.